TLDR: AI trading bots turned $10,000 into about $6,700 in two weeks, while Amgen dividend growth is framed as a sturdier compounding bet.
Key Takeaways:
- Nof1 gave Claude, ChatGPT, Gemini, Grok and others $10,000 to trade U.S. stocks for two weeks.
- The bot portfolio fell 33%, with Grok at 158 trades and models diverging, including Claude leaning long and Gemini short.
- Dividend momentum and buyback math are offered as an explanation for why Amgen may outperform patterns bots overfit.
The bots crash because they chase signals that look good in hindsight, then sprint into noise. Amgenās dividend runway is slower, louder in the long term, and harder for algorithms to fake.
The bots crash because they chase signals that look good in hindsight, then sprint into noise. Amgenās dividend runway is slower, louder in the long term, and harder for algorithms to fake.
Q&A
If bots can lose fast on short horizons, what should investors demand from AI tools before using them with real money?
Prove risk controls under strict limits, stress test transaction costs, and show performance across multiple market regimes, not just backtests.
Why did giving every model the same rules still produce wildly different trades and outcomes?
Different training data, prompt interpretation, and internal heuristics can create distinct bias and leverage behavior even under shared instructions.
What happens to a dividend magnet thesis if a biotech cut risk rises or a key drug stumbles?
The price can temporarily detach from the dividend narrative, so investors would need evidence that payout growth remains credible.
How does a buyback amplify dividend growth claims without changing the underlying drug pipeline?
Fewer shares can increase cash per share, making future dividend raises easier if operating cash flow stays steady.
If Wall Street targets cluster above the current price, what might delay the catch up?
Timelines for rare disease demand, reimbursement cycles, and incremental investor skepticism about one drug sidelined by broader pipeline gains.
No comments yet. Be the first to share your thoughts!